Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507972 | 0.82 | LRRK2 (0.50) | CES1MAOAMAOBLRRK2NPC1 | |
| SCHEMBL4586111 | 0.77 | CES1 (0.52) | CES1MAOAMAOBCA1CA2 | |
| SCHEMBL4996116 | 0.76 | TGM2 (0.48) | CES1NPC1CA1CA2CA7 | |
| SCHEMBL4996113 | 0.76 | TGM2 (0.48) | CES1NPC1CA1CA2CA7 | |
| SCHEMBL281203 | 0.75 | CES1 (0.60) | CES1MAOAMAOBLRRK2CA1 | |
| SCHEMBL30716604 | 0.75 | CES1 (1.00) | CES1MAOAMAOBPBRM1TGM2 | |
| SCHEMBL30835279 | 0.75 | CES1 (0.60) | CES1MAOAMAOBLRRK2MEN1 | |
| SCHEMBL2838571 | 0.75 | CES1 (0.60) | CES1MAOAMAOBLRRK2MEN1 | |
| SCHEMBL2136384 | 0.75 | CES1 (0.60) | CES1MAOAMAOBLRRK2CA1 | |
| SCHEMBL5975593 | 0.75 | CES1 (0.60) | CES1MAOAMAOBLRRK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | claimed |
| CN-111574426-A | Diamine monomer containing isoindigo structure and black polyimide synthesized from diamine monomer | 湘潭大学 | 2020-08-25 | — | — | CN | claimed |
| CN-110642773-A | Industrial preparation method of high-purity 4-fluoroisatin | 严学文 | 2020-01-03 | — | — | CN | claimed |
| CN-118388454-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-113912609-B | Preparation method of natural alkaloid tryptanthrin and derivatives thereof | 江苏大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022194399-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-22 | — | — | WO | disclosed |
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | disclosed |
| CN-110642773-A | Industrial preparation method of high-purity 4-fluoroisatin | 严学文 | 2020-01-03 | — | — | CN | disclosed |
| CN-103319395-A | Industrialization preparation method for 4-fluoroisatin and product thereby | WUHAN LUOHUA TECHNOLOGY CO LTD | 2013-09-25 | — | — | CN | disclosed |
| CN-103319395-A | Industrialization preparation method for 4-fluoroisatin and product thereby | WUHAN LUOHUA TECHNOLOGY CO LTD | 2013-09-25 | — | — | CN | disclosed |
| CN-101492410-B | Indirubin compounds for antineoplastic medicament | UNIV SHANGHAI JIAOTONG | 2011-06-22 | — | — | CN | disclosed |
| CN-101492410-A | Indirubin compounds for antineoplastic medicament | UNIV SHANGHAI JIAOTONG (CN) | 2009-07-29 | — | — | CN | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| EP-1888530-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| CN-100345844-C | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| WO-2006120478-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| CN-1434821-A | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | CES1 3004/4885MAOA 2271/4885MAOB 1627/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | CES1 1855/4885MAOA 4169/4885MAOB 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.